Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SupervisorsDr Ahmet Hazini, Dr Kerry Fisher

Project Overview

Macrophages possess unique attributes that make them highly relevant in the context of immuno-oncology. Firstly, they can efficiently sense and migrate to tumours, which explains why many solid tumours are enriched with macrophages. Another important feature is their remarkable plasticity: depending on environmental signals, they can adopt either anti-tumour or pro-tumour functions. Crucially, macrophages can also be reprogrammed to stimulate adaptive immune responses.  As professional antigen-presenting cells (APCs), macrophages have the potential to elicit adaptive immunity not only against primary tumours but also against disseminated ones. However, their antigen-presenting capacity is generally weaker compared to dendritic cells (DCs), which are considered the most potent APCs. A major limitation is that DCs are scarce within the tumour microenvironment (TME), whereas macrophages are abundant.  This project aims to employ molecular and cellular strategies to enhance the antigen-presenting ability of macrophages, thereby improving their capacity to drive effective adaptive immune responses and harness their potential as cellular cancer vaccines.

References

Yang, S., Wang, Y., Jia, J., Fang, Y., Yang, Y., Yuan, W. and Hu, J., 2024. Advances in engineered macrophages: a new frontier in cancer immunotherapy. Cell Death & Disease15(4), p.238.

https://www.nature.com/articles/s41556-024-01372-4